Source: Annual Congress 2010 - Experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Morecroft, B. Doyle, M. MacLean (Glasgow, United Kingdom). Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1066

Member's Comments

No comment yet.

Related content which might interest you: The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004 Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Homeodomain-interracting protein kinase 2 (HIPK2) in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Roflumilast N-oxide (RNO) increases MAP kinase phosphatase-1 (MKP-1) expression in human lung fibroblasts (HLF) Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017 MAPKAP Kinase 2-deficient mice show increased susceptibility to Pseudomonas aeruginosa infection Source: Annual Congress 2010 - Bronchiectasis and respiratory infections caused by Pseudomonas Year: 2010 IL18 induces p38 MAP kinase activation and adhesion capacities in BMPRII knocked down human lung microvascular endothelial cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells Source: Eur Respir J 2005; 26: Suppl. 49, 225s Year: 2005 Mitogen activated protein kinase activated protein kinase 2 regulates actin stress fiber formation in ventilator associated lung injury Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 The effect of smoking on phosphoinositide 3-kinase (PI3K) and phosphatase and tensin homolog deleted from chromosome 10 (PTEN) mRNA expression in human airway epithelial cells Source: International Congress 2014 – Mechanistic studies of the airway epithelium Year: 2014 Effects of glucocorticoids on activation of extracellular signal-regulated kinases (ERK) in human pulmonary endothelial cells Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021